- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01896115
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation (CUSTOM-DBS)
Current Steering to Optimize Deep Brain Stimulation
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study is a prospective, multi-center, double-blind, randomized controlled trial.
This study will compare various program settings for the bilateral stimulation of the STN using the BSC implantable Vercise™ DBS System for the treatment of levodopa-responsive, moderate to severe idiopathic PD.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Innsbruck, Austria
- A.o. LKH Univ.-Kliniken Innsbruck
-
-
-
-
-
Berlin, Niemcy
- University Berlin, Charite Virchow
-
Düsseldorf, Niemcy
- Universitaetsklinikum Dusseldorf
-
Kiel, Niemcy
- Universitätsklinikum Campus Kiel
-
Köln, Niemcy
- Uniklinik Koln
-
Wurzburg, Niemcy
- Universitaetsklinikum Wuerzburg
-
-
-
-
California
-
Valencia, California, Stany Zjednoczone, 91355
- Boston Scientific Clinical Research Information Toll Free Number
-
-
-
-
-
Udine, Włochy
- Osp. S. Maria Della Misericordia
-
-
-
-
-
Bristol, Zjednoczone Królestwo
- Southmead Hospital Bristol
-
London, Zjednoczone Królestwo
- Charing Cross Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Implanted bilaterally in STN with a Vercise DBS system for Parkinson's disease for at least three months with programming optimized according to standard of care.
- UPDRS subset III score of ≥30 in the in the pre-operative meds off state.
- DBS must improve PD symptoms by ≥30% in the meds off state, as measured by UPDRS subset III score.
- Medical and mental fitness to comply with programming visit and study related procedures.
- Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
- Off symptom rigidity score of ≥2 in the evaluated arm as determined by the UPDRS-III.
Exclusion Criteria:
- Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <12 months.
- Resting and/or action tremor score of ≥3 on the evaluated side as determined by the UPDRS-III in pre-operative meds off condition.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Short PW
Patients with a Vercise DBS system programmed to 30 microseconds pulse width
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
|
Eksperymentalny: Conventional PW
Patients with a Vercise DBS system programmed to 60 microseconds pulse width
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
|
Eksperymentalny: Ventral current steering
Patients with a Vercise DBS system programmed to steer current ventrally
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
|
Eksperymentalny: Dorsal current steering
Patients with a Vercise DBS system programmed to steer current dorsally.
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Therapeutic Window
Ramy czasowe: Day 1 programming visit
|
The therapeutic window refers to the range of stimulus amplitudes that provide a therapeutic effect without side effects.
In other words, it is the amplitude difference between the first stimulation-induced side effect threshold (e.g., eye deviation, muscle contraction, and speech) and full rigidity control threshold at 60 µs and 30 µs pulse width DBS settings.
|
Day 1 programming visit
|
|
Unified Parkinson's Disease Rating Scale III
Ramy czasowe: Day 1 programming visit
|
The Unified Parkinson's Disease Rating Scale (UPDRS) has four sections (I-IV) that ask patients to rate aspects of their mental state including mood (I), aspects of daily activities (II), aspects of motor function (III), and complications of treatment (IV). Here, we ask subjects to rate their motor function (UPDRS III) following interventions with 30 µs and 60 µs pulse width DBS settings. The UPDRS III scale has 14 categories including speech, facial expression, tremor at rest, action tremor, rigidity, finger tapping ability, ability to open and close hands, ability to rapidly alternate hand movements, leg agility, ability to rise from a chair, posture, gait, response to postural displacement (e.g., push), and bradykinesia. Patients rate each of these categories from 0 to 4, with 0 being normal function and 4 being the worst. Categories assessing appendages are rated for both left and right sides, allowing a maximum score (worst outcome) of 108. |
Day 1 programming visit
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Side Effect Thresholds - Single Contact vs. Steering
Ramy czasowe: Day 1 programming visit
|
This endpoint determined how much current (mA) could be applied before side effects appeared when using 60 microsecond pulse widths.
Values were obtained for when current was delivered through a single contact or divided between two contacts (steering).
|
Day 1 programming visit
|
|
Resting Tremor Severity - Single Contact vs. Steering
Ramy czasowe: Day 1 programming visit
|
Resting tremor was measured by a motion sensor system (Kinesia System) while either using a single contact or steering current between two contacts.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
|
Finger Tapping Amplitude - Single Contact vs. Steering
Ramy czasowe: Day 1 programming visit
|
Severity of finger-tapping bradykinesia was measured by a motion sensor system (Kinesia System) when either using a single contact or steering current between two contacts.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Dorsal-Ventral Current Steering Therapeutic Window
Ramy czasowe: Day 1 programming visit
|
The therapeutic window refers to the range of stimulus amplitudes that provide a therapeutic effect without side effects.
In other words, this measure reports the stimulus amplitude difference between the full rigidity control threshold and the first stimulation induced side effect threshold at current steering settings (current divided 50% between adjacent electrodes).
|
Day 1 programming visit
|
|
Resting Tremor Severity - Pulse Width and Dorsal-Ventral Steering
Ramy czasowe: Day 1 programming Visit
|
Resting tremor was measured by a motion sensor system (Kinesia System) at 60 µs, 30 µs, and current steering settings, at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming Visit
|
|
Finger Tapping Amplitude - Pulse Width and Dorsal-Ventral Steering
Ramy czasowe: Day 1 programming visit
|
Severity of finger-tapping bradykinesia was measured by a motion sensor system (Kinesia System) at 60 µs, 30 µs, and dorsal and ventral current steering settings.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- A4009
- CDM00060272 (Inny identyfikator: BSC Protocol Number)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Choroba Parkinsona
-
Peking University Third HospitalJeszcze nie rekrutacjaCentral Compartment Atopic Disease (CCAD)Chiny
-
Bambino Gesù Hospital and Research InstituteZakończonyCiężka otyłość dziecięca (BMI > 97° szt. -według wykresów BMI Centers for Disease Control and Prevention-) | Zmienione testy czynnościowe wątroby | Nietolerancja glikemicznaWłochy
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
-
Janssen Pharmaceutical K.K.ZakończonyOporna na leczenie Mycobacterium Avium Complex-lung Disease (MAC-LD)Tajwan, Japonia, Korea Południowa
-
Adelphi Values LLCBlueprint Medicines CorporationZakończonyBiałaczka z komórek tucznych (MCL) | Agresywna mastocytoza układowa (ASM) | SM w Assoc Clonal Hema Lineage Non-mast Cell Lineage Disease (SM-AHNMD) | Tląca się mastocytoza układowa (SSM) | Indolentna układowa mastocytoza (ISM) Podgrupa ISM w pełni zatrudnionaStany Zjednoczone
Badania kliniczne na Vercise DBS settings
-
University Hospital FreiburgBoston Scientific CorporationZakończony
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...Aktywny, nie rekrutujący
-
University of Alabama at BirminghamMichael J. Fox Foundation for Parkinson's ResearchZakończonyChoroba Parkinsona | Dystonia-parkinsonizm, początek w wieku dorosłymStany Zjednoczone
-
Jonathan JagidBoston Scientific CorporationZakończonyChoroba ParkinsonaStany Zjednoczone
-
Boston Scientific CorporationZakończonyChoroba ParkinsonaStany Zjednoczone
-
Vanderbilt University Medical CenterBoston Scientific CorporationRejestracja na zaproszenieDemencja | Choroba Alzheimera | Choroba Alzheimera, wczesny początekStany Zjednoczone
-
Boston Scientific CorporationRekrutacyjnyChoroba ParkinsonaStany Zjednoczone, Niemcy, Belgia, Włochy, Polska, Hiszpania, Austria, Francja, Izrael, Zjednoczone Królestwo, Kanada, Węgry, Korea Południowa, Turcja (Türkiye), Argentyna
-
donald whitingBoston Scientific CorporationWycofaneOtyłośćStany Zjednoczone
-
Boston Scientific CorporationRekrutacyjnyDystoniaNiemcy, Włochy, Polska, Hiszpania, Zjednoczone Królestwo, Kanada, Węgry, Belgia, Izrael, Holandia, Rosja, Korea Południowa
-
Allegheny Singer Research Institute (also known...Boston Scientific CorporationZakończonyChoroba Parkinsona | Głęboka stymulacja mózguStany Zjednoczone